Citation Impact
Citing Papers
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
2011 Standout
In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase
2009
V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway
2009
Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
2014
Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
2012
Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
2013
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma
2015
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
2012
Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation
2011
Development of siRNA Payloads to Target KRAS -Mutant Cancer
2014
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Microsatellite Instability, Mismatch Repair Deficiency, and BRAF Mutation in Treatment-Resistant Germ Cell Tumors
2009
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Cancer statistics, 2022
2022 Standout
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
2012 Standout
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Eradication therapy for peptic ulcer disease in Helicobacter pylori -positive people
2016
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
2010
Cerebrovascular disease in ageing and Alzheimer’s disease
2015
Cancer Statistics, 2021
2021 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
MEK1/2 inhibitors in the treatment of gynecologic malignancies
2014
Pathophysiology of Progressive Nephropathies
1998 Standout
MEK in cancer and cancer therapy
2013
Thyroid cancer
2016 Standout
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
2013
Hepatocellular carcinoma
2016 Standout
Cancer to bone: a fatal attraction
2011 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Spotlight on Bicalutamide 150mg in the Treatment of Locally Advanced Prostate Cancer1
2007
Innate and adaptive immune cells in the tumor microenvironment
2013 Standout
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
2013
How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett’s esophagus
2007
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease
2017 Standout
Liquid biopsy enters the clinic — implementation issues and future challenges
2021
Melanoma: New Insights and New Therapies
2012
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
2008
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett’s oesophagus: a randomised trial
2004
Esophageal Cancer
2003 Standout
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
RAS-targeted therapies: is the undruggable drugged?
2020
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
2015
Targeting Mutant BRAF in Melanoma
2012
American Gastroenterological Association Technical Review on the Role of the Gastroenterologist in the Management of Esophageal Carcinoma
2005
Lung cancer: current therapies and new targeted treatments
2016 Standout
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
2012
Oesophageal carcinoma
2013 Standout
EAU Guidelines on Prostate Cancer
2007 Standout
The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus
2006 Standout
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
2013
Zibotentan for the treatment of castrate-resistant prostate cancer
2010
Cancer immunotherapy comes of age
2011 StandoutNature
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches
2011
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
2012
Photodynamic therapy of cancer: An update
2011 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Pancreatic Cancer
2010 Standout
Prospects for MEK inhibitors for treating cancer
2014
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus
2008 Standout
Influence of Clinical and Histological Features on Actuarial Renal Survival in Adult Patients With Idiopathic IgA Nephropathy, Membranous Nephropathy, and Membranoproliferative Glomerulonephritis: Survey of the Recent Literature
1992
Targeting the RAS pathway in melanoma
2011
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
The PI3K Pathway in Human Disease
2017 Standout
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
2007
MEK Inhibition in the Treatment of Advanced Melanoma
2013
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
2009
Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma
2011
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies
2015
Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force
2016
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Improving Prospects for Targeting RAS
2015
Release of platelet constituents by monosodium urate crystals.
1977
Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study
1999 Standout
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
2008 StandoutNobel
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
2015
BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
2010
Oxidative Stress: An Essential Factor in the Pathogenesis of Gastrointestinal Mucosal Diseases
2014 Standout
Metabolic reprogramming and cancer progression
2020 StandoutScience
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
2011
Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy
2009
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
UV Radiation and the Skin
2013 Standout
Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus
2005
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
2006
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Targeting Bone Metastasis in Prostate Cancer with Endothelin Receptor Antagonists
2006
Works of Clive Morris being referenced
The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
2010
Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence
2005
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
2010
The Helicobacter Eradication Aspirin Trial (HEAT): A Large Simple Randomised Controlled Trial Using Novel Methodology in Primary Care
2015
A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
2010
Bicalutamide (‘Casodex’) 150mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme
2005
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
2008
Observations on the Effect of Glass Beads on Platelet Aggregation and Its Relation to Platelet Stickiness
1968
Diagnostic value of creatine kinase and creatine kinase MB isoenzyme in chronic hemodialysis patients: a longitudinal study.
1986
Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
2019
Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation
2001
The Bicalutamide 150 Mg Early Prostate Cancer Program: Findings of the North American Trial at 7.7-Year Median Followup
2006